Return to Intended Oncologic Treatment (RIOT): A Novel Metric for Evaluating the Quality of Oncosurgical Therapy for Malignancy

被引:143
作者
Aloia, Thomas A. [1 ]
Zimmitti, Giuseppe [1 ]
Conrad, Claudius [1 ]
Gottumukalla, Vijaya [2 ]
Kopetz, Scott [3 ]
Vauthey, Jean-Nicolas [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Anesthesia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
surgical oncology; adjuvant therapy; colorectal liver metastases; minimally invasive surgery; outcomes; COLORECTAL LIVER METASTASES; ADJUVANT CHEMOTHERAPY; HEPATIC RESECTION; SURGICAL RESECTION; DOSE INTENSITY; BREAST-CANCER; PHASE-III; SURVIVAL; SURGERY; RECURRENCE;
D O I
10.1002/jso.23626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After cancer surgery, complications, and disability prevent some patients from receiving subsequent treatments. Given that an inability to complete all intended cancer therapies might negate the oncologic benefits of surgical therapy, strategies to improve return to intended oncologic treatment (RIOT), including minimally invasive surgery (MIS), are being investigated. Methods: This project was designed to evaluate liver tumor patients to determine the RIOT rate, risk factors for inability to RIOT, and its impact on survivals. Outcomes for a homogenous cohort of 223 patients who underwent open-approach surgery for metachronous colorectal liver metastases and a group of 27 liver tumor patients treated with MIS hepatectomy were examined. Results: Of the 223 open-approach patients, 167 were offered postoperative therapy, yielding a RIOT rate of 75%. The remaining 56 (25%) patients were unable to receive further treatment due to surgical complications (n = 29 pts) or poor performance status (n = 27 pts). Risk factors associated with inability to RIOT were hypertension (OR 2.2, P = 0.025), multiple preoperative chemotherapy regimens (OR 5.9, P = 0.039), and postoperative complications (OR 2.0, P = 0.039). Inability to RIOT correlated with shorter disease-free and overall survivals (P < 0.001, HR = 2.16; and P = 0.005, HR 2.07, respectively). In contrast to the open surgery group, 100% of MIS patients who were intended to initiate postoperative therapy did so (P 0.038) within a shorter median time interval (MIS: 15 days vs. open: 42 days; P < 0.001). Conclusions: The relationship between RIOT and long-term oncologic outcomes suggests that RIOT rates for both open-and MIS-approach cancer surgery should routinely be reported as a quality indicator. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 38 条
[1]   The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus [J].
Adam, Rene ;
De Gramont, Aimery ;
Figueras, Joan ;
Guthrie, Ashley ;
Kokudo, Norihiro ;
Kunstlinger, Francis ;
Loyer, Evelyne ;
Poston, Graeme ;
Rougier, Philippe ;
Rubbia-Brandt, Laura ;
Sobrero, Alberto ;
Tabernero, Josep ;
Teh, Catherine ;
Van Cutsem, Eric .
ONCOLOGIST, 2012, 17 (10) :1225-1239
[2]   Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Petrelli, Nicholas J. ;
Colangelo, Linda H. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
Goldberg, Richard M. ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Lopa, Samia ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16
[3]   Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection [J].
Aloia, TA ;
Zorzi, D ;
Abdalla, EK ;
Vauthey, JN .
ANNALS OF SURGERY, 2005, 242 (02) :172-177
[4]   Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases [J].
Aloia, Thomas ;
Sebagh, Mylene ;
Plasse, Marylene ;
Karam, Vincent ;
Levi, Francis ;
Giacchetti, Sylvie ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis ;
Adam, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :4983-4990
[5]   Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy? [J].
Aloia, Thomas E. ;
Lee, Jeffrey E. ;
Vauthey, Jean-Nicolas ;
Abdalla, Eddie K. ;
Wolff, Robert A. ;
Varadhachary, Gauri R. ;
Abbruzzese, James L. ;
Crane, Christopher H. ;
Evans, Douglas B. ;
Pisters, Peter W. T. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (03) :347-355
[6]  
[Anonymous], 2002, P ASCO
[7]  
[Anonymous], 2000, HPB, DOI [DOI 10.1016/S1365-182X(17)30755-4, 10.1016/S1365-182X(17)30755-4]
[8]  
[Anonymous], 2003, P AM SOC CLIN ONCOL
[9]   30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [J].
Bonadonna, G ;
Moliterni, A ;
Zambetti, M ;
Daidone, MG ;
Pilotti, S ;
Gianni, L ;
Valagussa, P .
BRITISH MEDICAL JOURNAL, 2005, 330 (7485) :217-220
[10]   DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15